NCT06548217 - A Phase I Study of ONO-4538HSC in Subjects With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 7, 2024

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG

ONO-4538HSC

ONO-4538HSC will be administered subcutaneously once every 4 weeks.

Trial Locations (8)

National Cancer Center Hospital East, Kashiwa-shi

Tohoku University Hospital, Sendai

Niigata Cancer Center Hospital, Niigata

Osaka International Cancer Institute, Osaka

Kindai University Hospital, Osakasayama-shi

Shizuoka Cancer Center, Sunto-gun

National Cancer Center Hospital, Chuo-ku

The Cancer Institute Hospital Of JFCR, Koto-ku